Curis, Inc. (CRIS)

NASDAQ: CRIS · Real-Time Price · USD
1.300
+0.010 (0.78%)
Apr 17, 2025, 4:00 PM EDT - Market closed
0.78%
Market Cap 11.12M
Revenue (ttm) 10.91M
Net Income (ttm) -43.39M
Shares Out 8.49M
EPS (ttm) -6.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 75,450
Open 1.250
Previous Close 1.290
Day's Range 1.250 - 1.320
52-Week Range 1.020 - 16.990
Beta 3.51
Analysts Strong Buy
Price Target 21.00 (+1,515.39%)
Earnings Date May 6, 2025

About CRIS

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with r... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 1, 2000
Employees 34
Stock Exchange NASDAQ
Ticker Symbol CRIS
Full Company Profile

Financial Performance

In 2024, Curis's revenue was $10.91 million, an increase of 8.83% compared to the previous year's $10.02 million. Losses were -$43.39 million, -8.49% less than in 2023.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CRIS stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 1,515.39% from the latest price.

Price Target
$21.0
(1,515.39% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Curis to Present at Upcoming Healthcare Conference in April

LEXINGTON, Mass. , April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...

16 days ago - PRNewsWire

Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Diantha Duvall - CFO Jim Dentzer - President and CEO Jonathan Zung - Chief Development Office...

18 days ago - Seeking Alpha

Curis Provides Fourth Quarter 2024 Business Update

FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU Orphan Drug Designation for PCNSL granted in both US and EU Management to host conference call toda...

18 days ago - PRNewsWire

Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025

LEXINGTON, Mass. , March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inh...

21 days ago - PRNewsWire

Curis Announces Additional Data from TakeAim Leukemia Study

LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...

4 months ago - PRNewsWire

Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer...

5 months ago - Seeking Alpha

Curis Provides Third Quarter 2024 Business Update

Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.

5 months ago - PRNewsWire

Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

LEXINGTON, Mass. , Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...

5 months ago - PRNewsWire

Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement

LEXINGTON, Mass. , Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...

6 months ago - PRNewsWire

Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

Symposium hosted by Eric S. Winer, MD, and Grzegorz S.

7 months ago - PRNewsWire

Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference

LEXINGTON, Mass. , Sept. 17, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inh...

7 months ago - PRNewsWire

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass. , Sept. 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...

8 months ago - PRNewsWire

Curis, Inc. (CRIS) Q2 2024 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President and CEO Jonathan Zung - Chie...

9 months ago - Seeking Alpha

Curis Provides Second Quarter 2024 Financial and Operating Update

EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass.

9 months ago - PRNewsWire

Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

LEXINGTON, Mass. , July 25, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...

9 months ago - PRNewsWire

Curis to Present at Upcoming Healthcare Conference in July

LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...

10 months ago - PRNewsWire

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass. , July 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...

10 months ago - PRNewsWire

Curis to Present Updated Data from the TakeAim Leukemia Study

LEXINGTON, Mass. , May 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...

1 year ago - PRNewsWire

Curis, Inc. (CRIS) Q1 2024 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Diantha Duvall - CFO Jim Dentzer - President & CEO Robert Martell - Chief Scientific Officer Con...

1 year ago - Seeking Alpha

Curis Provides First Quarter 2024 Business Update

Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.

1 year ago - PRNewsWire

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024

LEXINGTON, Mass. , April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inh...

1 year ago - PRNewsWire

Curis to Present at Upcoming Healthcare Conferences in April

LEXINGTON, Mass. , April 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

1 year ago - PRNewsWire

Curis, Inc. (CRIS) Q4 2023 Earnings Call Transcript

Curis, Inc. (CRIS) Q4 2023 Earnings Call Transcript

1 year ago - Seeking Alpha

Curis Provides Fourth Quarter 2023 Business Update

Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host conference call toda...

1 year ago - PRNewsWire

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

LEXINGTON, Mass. , Feb. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...

1 year ago - PRNewsWire